Biochemical recurrence after radical prostatectomy presents a common clinical dilemma in prostate cancer management. Radiation oncologists frequently utilize salvage radiotherapy to eradicate persistent local or regional microscopic disease before systemic dissemination occurs. Historically, standard fractionated protocols delivered treatment across six to seven weeks, demanding considerable clinical resources and patient commitment. However, recent advances in radiation biology and delivery technology have led to the investigation of shorter treatment courses. The phase III randomized clinical trial comparing salvage hypofractionated radiotherapy with standard radiotherapy provides definitive insights into oncologic control, treatment toxicity, and patient-reported outcomes.

Background and Rationale for Salvage Hypofractionated Radiotherapy

Prostate cancer cells exhibit high radiation fraction sensitivity due to an estimated low alpha-to-beta ratio. Consequently, delivering larger doses per fraction over a reduced number of treatment days can potentially enhance therapeutic efficacy or maintain equivalent tumor control while shortening total therapy duration. In definitive, intact-organ settings, multiple randomized studies have established moderate hypofractionation as an accepted standard of care. Nevertheless, radiation oncologists historically approached the post-prostatectomy salvage setting with greater caution. The proximity of the bladder neck, vesicourethral anastomosis, and rectum after surgery elevates concerns regarding late genitourinary and gastrointestinal complications.

Early prospective post-prostatectomy investigations suggested that moderately hypofractionated schedules could deliver non-inferior patient-reported toxicity profiles. However, oncologists required robust, long-term phase III efficacy data to validate these regimens against traditional standard-fractionation salvage schedules. Clinicians aimed to determine whether accelerated dose delivery could improve biochemical progression-free survival without inducing unacceptable late normal-tissue injury. The prospective phase III trial rigorously addresses this vital clinical question by comparing an accelerated 26-fraction regimen with a standard 33-fraction protocol in intermediate- and high-risk patients.

Trial Design and Patient Stratification

The multicenter phase III study recruited 316 patients presenting with intermediate- to high-risk prostate cancer experiencing biochemical recurrence after radical prostatectomy between 2019 and 2021. Investigators randomly allocated participants into two distinct treatment arms. The hypofractionated group received 65 Gy delivered in 26 fractions of 2.5 Gy each, whereas the conventional standard group received 66 Gy delivered in 33 fractions of 2.0 Gy each.

All treatments targeted the prostatic bed using advanced intensity-modulated radiotherapy with daily image guidance to ensure high delivery accuracy. Furthermore, treating radiation oncologists administered elective pelvic nodal irradiation at their discretion, which was delivered in 68.5% of participants. Concomitant androgen deprivation therapy was prescribed to 51.2% of enrolled patients, reflecting modern comprehensive risk-adapted oncologic management. The median pre-radiotherapy prostate-specific antigen level stood at 0.36 ng/mL. Additionally, radiation oncology teams implemented endorectal balloons during treatment in 63.1% of patients to stabilize the prostate bed and displace posterior rectal mucosa away from high radiation doses.

Efficacy and Oncologic Outcomes at Four Years

The primary end point of the randomized investigation evaluated biochemical progression-free survival at four years following completion of salvage therapy. After a comprehensive median follow-up duration of 52.6 months, the 4-year biochemical progression-free survival reached 80.1% in the hypofractionated cohort and 78.1% in the conventional radiotherapy cohort. This prospective comparison revealed that the hypofractionated protocol did not achieve statistical superiority over conventional radiotherapy.

Nevertheless, the data confirmed highly comparable disease control rates across all major secondary oncologic measures. The 4-year distant metastasis-free survival rate stood at 91.7% in the hypofractionated cohort compared to 91.0% in the conventional arm. Moreover, cancer-specific survival reached 100% across both treatment arms, illustrating robust cancer suppression with both regimens when initiated at low post-operative prostate-specific antigen thresholds. These oncologic findings confirm that accelerating the delivery timeline to 26 fractions preserves long-term tumor control without compromising biochemical or metastatic endpoints.

Safety Profiles and the Impact of Endorectal Balloons

Evaluating normal tissue toxicity represents a critical component of assessing hypofractionated radiotherapy. In this trial, the overall incidence of high-grade toxicities remained low across both treatment cohorts. However, investigators observed a statistically higher 4-year cumulative incidence of grade 2 or greater gastrointestinal toxicity in the hypofractionated arm at 7.9%, compared to 0.7% in the conventional radiotherapy arm.

Importantly, detailed subgroup analysis revealed that this elevated gastrointestinal toxicity occurred almost exclusively among individuals treated without an endorectal balloon. Patients managed with an endorectal balloon demonstrated substantially lower rates of adverse rectal events, underscoring the protective role of rectal displacement and immobilization. Furthermore, all documented grade 2 or greater gastrointestinal toxicities fully resolved prior to the final clinical follow-up visit. Regarding genitourinary morbidity, investigators observed no significant divergence between the study groups. Patient-reported quality-of-life assessments demonstrated virtually identical functional outcomes across domains, confirming that accelerated salvage treatment does not undermine long-term well-being.

Clinical Implications and Future Directions

These phase III results establish moderate hypofractionation as a clinically viable and practical alternative to standard prolonged fractionation for salvage post-prostatectomy radiotherapy. While the study did not demonstrate superiority in disease-free control, the equivalence in biochemical progression-free survival, metastasis prevention, and patient-reported health domains provides strong reassurance. Shortening the treatment schedule from 33 fractions down to 26 fractions saves seven full treatment visits, thereby substantially reducing health system burdens and patient travel expenses.

Given the modest increase in grade 2 gastrointestinal toxicity observed in unshielded patients, radiation teams should implement meticulous organ-at-risk sparing techniques. The routine integration of endorectal balloons, rectal hydrogel spacers, or precise daily image guidance can mitigate mucosal dose accumulation. Clinicians must continue evaluating longer-term post-treatment registry data and biomarker stratification to identify optimal candidates for accelerated regimens. Ultimately, offering an accelerated salvage course empowers patients and clinicians to optimize cancer control while respecting resource constraints and lifestyle priorities.

Frequently Asked Questions

What was the primary end point of this phase III trial?

The primary end point was four-year biochemical progression-free survival following salvage radiotherapy for prostate cancer recurrence. Secondary end points evaluated distant metastasis-free survival, prostate cancer-specific survival, adverse event profiles, and patient-reported quality-of-life outcomes. The study demonstrated comparable four-year biochemical progression-free survival rates between the 26-fraction hypofractionated regimen and the standard 33-fraction schedule.

Did hypofractionated salvage radiotherapy increase toxicities?

The hypofractionated cohort showed a slightly higher cumulative incidence of grade 2 or greater gastrointestinal toxicity compared to conventional fractionation. However, this toxicity occurred predominantly among patients treated without an endorectal balloon. Importantly, all reported gastrointestinal adverse events resolved completely by final follow-up, and patient-reported overall quality-of-life scores remained equivalent between both treatment groups.

Can hypofractionated radiotherapy be adopted in routine clinical settings?

Hypofractionated salvage radiotherapy reduces the overall treatment schedule from 33 daily sessions down to 26 fractions. This acceleration saves patients more than one full week of clinical visits, reducing financial, logistic, and emotional burdens. Because oncologic control and long-term quality-of-life outcomes remain equivalent, hypofractionation represents an efficient and convenient treatment alternative for biochemical recurrence.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace clinical judgment. Consult qualified healthcare professionals and institutional protocols before making diagnostic or treatment decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Song Y et al. Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial. J Clin Oncol. 2026 Aug 25. doi: 10.1200/JCO-25-02234. PMID: 42641124.


2. Buyyounouski MK, Pugh SL, Chen RC, et al. Hypofractionated vs Conventionally Fractionated Postprostatectomy Radiotherapy for Prostate Cancer: The NRG-GU003 Randomized Clinical Trial. JAMA Oncol. 2024;10(4):485-492.


3. Pisansky TM, Agrawal S, Hamstra DA, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024;211(4):534-541.


4. Park G, Kim YJ, Ahn H, et al. Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial. Trials. 2021;22(1):728.